Haermonics Series A funding offers Pure™ promise for future heart surgery patients

Haermonics, a clinical-stage breakthrough medtech company, has successfully closed a 4.3 M Series-A financing round with an investment syndicate led by existing shareholder BOM, strategic partner Demcon and Stepping Stone (a fund managed by healthtech venture builder NLC), further including impact investor Invest-nl and a group of strategic private co-investors. Haermonics’ innovative and highly effective flush therapy – the Haermonics Pure™ therapy – demonstratively prevents post-operative cardiac surgery complications. Every day 250 patients die from postoperative heart surgery complications caused by residual blood and clots in the pericardial cavity. With this latest round of funding, such complications are
closer to being a thing of the past.

Read the full press release by Haermonics on LinkedIn >